Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amylyx Pharmaceuticals
Biotech
Amylyx GLP-1 inhibitor halves blood sugar crashes in ph. 3 win
Amylyx’s $35 million bet on the GLP-1 antagonist avexitide appears to have paid off, with the molecule halving dangerous blood sugar crashes.
Darren Incorvaia
Aug 18, 2026 7:01am
Amylyx discontinues rare neuro program after missing ph. 2 mark
Aug 27, 2025 10:40am
FDA lifts clinical hold on Amylyx ALS trial
Jan 21, 2025 10:35am
Amylyx preps for GLP-1 launch with new CCO—Chutes & Ladders
Jan 10, 2025 8:30am
Amylyx CEOs take hard lessons to rebuild the pipeline
Jul 10, 2024 7:00am
Amylyx seeks to fill Relyvrio-sized hole with $35M GLP-1 buy
Jun 24, 2024 10:18am
